Details of the Drug

General Information of Drug (ID: DMCA9QP)

• Drug Name: Papaverine
• Synonyms: papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE

Indication

Disease Entry	ICD 11	Status	REF
Brain ischaemia	8B1Z	Approved	[1]
Spasm	MB47.3	Approved	[2]
Peripheral vascular disease	BD4Z	Investigative	[3]

• Therapeutic Class: Vasodilator Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  A03AD01: Papaverine
  A03AD: Papaverine and derivatives
  A03A: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
  A03: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
  A: ALIMENTARY TRACT AND METABOLISM
  A03AD01: Papaverine
  A03AD: Papaverine and derivatives
  A03A: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
  A03: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
  A: ALIMENTARY TRACT AND METABOLISM
  G04BE02: Papaverine
  G04BE: Drugs used in erectile dysfunction
  G04B: UROLOGICALS
  G04: UROLOGICALS
  G: GENITO URINARY SYSTEM AND SEX HORMONES
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 339.4
  Logarithm of the Partition Coefficient (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 0.5 - 2 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.2554 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.073% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1 L/kg [4]
• Chemical Identifiers:
  Formula: C20H21NO4
  IUPAC Name: 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
  Canonical SMILES: COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
  InChI: InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
  InChIKey: XQYZDYMELSJDRZ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4680
  ChEBI ID: CHEBI:28241
  CAS Number: 58-74-2
  UNII: DAA13NKG2Q
  DrugBank ID: DB01113
  TTD ID: D0NJ3V
  VARIDT ID: DR00967
  INTEDE ID: DR2299
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 4D (PDE4D)	TTSKMI8	PDE4D_HUMAN	Inhibitor	[6]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[8]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Gene/Protein Processing	[9]
Cystic fibrosis transmembrane conductance regulator (CFTR)	OT6B22QH	CFTR_HUMAN	Gene/Protein Processing	[10]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[11]
Hepcidin (HAMP)	OT607RBL	HEPC_HUMAN	Gene/Protein Processing	[12]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Gene/Protein Processing	[8]

Molecular Expression Atlas of This Drug

• The Studied Disease: Brain ischaemia
• ICD Disease Classification: 8B1Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 5A (PDE5A)	DTT	PDE5A	1.60E-01	-0.25	-0.99

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Papaverine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[13]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Papaverine and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Idarubicin.	Acute myeloid leukaemia [2A60]	[13]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Papaverine and Arn-509.	Acute myeloid leukaemia [2A60]	[13]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Papaverine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[13]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Papaverine and Oliceridine.	Acute pain [MG31]	[14]
Ivabradine	DM0L594	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ivabradine.	Angina pectoris [BA40]	[13]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Dronedarone.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Papaverine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[13]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Posaconazole.	Aspergillosis [1F20]	[13]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[13]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[13]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Papaverine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Papaverine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Papaverine and Retigabine.	Behcet disease [4A62]	[13]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Papaverine and Cariprazine.	Bipolar disorder [6A60]	[15]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Papaverine and Eribulin.	Breast cancer [2C60-2C6Y]	[13]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lapatinib.	Breast cancer [2C60-2C6Y]	[13]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Papaverine and Bosutinib.	Breast cancer [2C60-2C6Y]	[13]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Papaverine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[13]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Halothane.	Corneal disease [9A76-9A78]	[13]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sevoflurane.	Corneal disease [9A76-9A78]	[13]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Papaverine and Probucol.	Coronary atherosclerosis [BA80]	[13]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pasireotide.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Papaverine and Osilodrostat.	Cushing syndrome [5A70]	[13]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Papaverine and Isocarboxazid.	Depression [6A70-6A7Z]	[16]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Escitalopram.	Depression [6A70-6A7Z]	[13]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Papaverine and OPC-34712.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Clomipramine.	Depression [6A70-6A7Z]	[13]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Papaverine and Doxepin.	Depression [6A70-6A7Z]	[13]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Papaverine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[13]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Papaverine and Deutetrabenazine.	Dystonic disorder [8A02]	[13]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ingrezza.	Dystonic disorder [8A02]	[13]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Papaverine and Solifenacin.	Functional bladder disorder [GC50]	[13]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Papaverine and Procarbazine.	Hodgkin lymphoma [2B30]	[16]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Papaverine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Papaverine and ITI-007.	Insomnia [7A00-7A0Z]	[15]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Papaverine and Crizotinib.	Lung cancer [2C25]	[13]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Osimertinib.	Lung cancer [2C25]	[13]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Papaverine and Selpercatinib.	Lung cancer [2C25]	[13]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lumefantrine.	Malaria [1F40-1F45]	[13]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Papaverine and Halofantrine.	Malaria [1F40-1F45]	[13]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Papaverine and Hydroxychloroquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Papaverine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[13]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[13]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Vemurafenib.	Melanoma [2C30]	[13]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Panobinostat.	Multiple myeloma [2A83]	[13]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Papaverine and Siponimod.	Multiple sclerosis [8A40]	[17]
Fingolimod	DM5JVAN	Major	Increased risk of prolong QT interval by the combination of Papaverine and Fingolimod.	Multiple sclerosis [8A40]	[13]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Papaverine and Ozanimod.	Multiple sclerosis [8A40]	[18]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Romidepsin.	Mycosis fungoides [2B01]	[13]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Papaverine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[13]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Papaverine and Entrectinib.	Non-small cell lung cancer [2C25]	[13]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[13]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lofexidine.	Opioid use disorder [6C43]	[13]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Papaverine and Rucaparib.	Ovarian cancer [2C73]	[13]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Triclabendazole.	Parasitic worm infestation [1F90]	[13]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Papaverine and Safinamide.	Parkinsonism [8A00]	[16]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Papaverine and Rasagiline.	Parkinsonism [8A00]	[16]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pimavanserin.	Parkinsonism [8A00]	[13]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[13]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lefamulin.	Pneumonia [CA40]	[13]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Papaverine and Degarelix.	Prostate cancer [2C82]	[13]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Papaverine and Enzalutamide.	Prostate cancer [2C82]	[13]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Relugolix.	Prostate cancer [2C82]	[13]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Papaverine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Papaverine and Quetiapine.	Schizophrenia [6A20]	[13]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Papaverine and Aripiprazole.	Schizophrenia [6A20]	[15]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Papaverine and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Papaverine and Paliperidone.	Schizophrenia [6A20]	[15]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Papaverine and Molindone.	Schizophrenia [6A20]	[15]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Papaverine and Amisulpride.	Schizophrenia [6A20]	[13]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Papaverine and Asenapine.	Schizophrenia [6A20]	[13]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Papaverine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Papaverine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pitolisant.	Somnolence [MG42]	[13]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Papaverine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Cabozantinib.	Thyroid cancer [2D10]	[13]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Papaverine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Papaverine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Papaverine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Papaverine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[13]

References

• [1] Intra-Arterial Papaverine-Hydrochloride and Transluminal Balloon Angioplasty for Neurointerventional Management of Delayed-Onset Post-Aneurysmal Subarachnoid Hemorrhage Vasospasm. World Neurosurg. 2018 Nov;119:e301-e312.
• [2] Drug information of Papaverine, 2008. eduDrugs.
• [3] Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic. Diabet Med. 1995 Jan;12(1):77-82.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [7] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [8] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [9] Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
• [10] Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
• [11] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [12] A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
• [13] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [14] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [15] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [16] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [17] Cerner Multum, Inc. "Australian Product Information.".
• [18] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.